Maryland HB417 regulates the sale and distribution of medetomidine and xylazine products, requiring proof of intended use and age verification.

Maryland HB417 amends the Health – General Article to establish the Medetomidine and Xylazine Consumer Protection Act. The Act mandates that retailers selling medetomidine or xylazine products require proof of the purchaser's intended use and age verification. Retailers must maintain records of all sales, including identification and proof of intended use. Violators face civil penalties, with $3,000 for a first offense and $6,500 for subsequent offenses. All collected penalties are to be remitted to the Comptroller and deposited into the Maryland Substance Abuse Fund.

Maryland HB417 regulates the sale and distribution of medetomidine and xylazine products, requiring proof of intended use and age verification.

Maryland HB417 amends the Health – General Article to establish the Medetomidine and Xylazine Consumer Protection Act. The Act mandates that retailers selling medetomidine or xylazine products require proof of the purchaser's intended use and age verification. Retailers must maintain records of all sales, including identification and proof of intended use. Violators face civil penalties, with $3,000 for a first offense and $6,500 for subsequent offenses. All collected penalties are to be remitted to the Comptroller and deposited into the Maryland Substance Abuse Fund.